First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models

[1]  D. Morris,et al.  Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing , 2013, Journal of Medical Genetics.

[2]  B. Raaka,et al.  Thyrotropin-Releasing Hormone Receptor Type 1 (TRH-R1), not TRH-R2, Primarily Mediates Taltirelin Actions in the CNS of Mice , 2013, Neuropsychopharmacology.

[3]  L. Mucke,et al.  Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. , 2012, Cold Spring Harbor perspectives in medicine.

[4]  Y. Michotte,et al.  Ghrelin: An emerging new anticonvulsant neuropeptide , 2012, Epilepsia.

[5]  L. Mucke,et al.  Alzheimer Mechanisms and Therapeutic Strategies , 2012, Cell.

[6]  J. Hardy,et al.  Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. , 2012, Brain : a journal of neurology.

[7]  T. Hortobágyi,et al.  p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS , 2011, Acta Neuropathologica.

[8]  M. Iigo,et al.  Molecular cloning, molecular evolution and gene expression of cDNAs encoding thyrotropin-releasing hormone receptor subtypes in a teleost, the sockeye salmon (Oncorhynchus nerka). , 2011, General and comparative endocrinology.

[9]  W. Geldenhuys,et al.  The emergence of designed multiple ligands for neurodegenerative disorders , 2011, Progress in Neurobiology.

[10]  L. Bianchi,et al.  Highly reactive oxygen species: detection, formation, and possible functions , 2011, Cellular and Molecular Life Sciences.

[11]  M. Beal,et al.  Neuroprotective effects of creatine , 2011, Amino Acids.

[12]  S. Petri,et al.  Significance of behavioural tests in a transgenic mouse model of amyotrophic lateral sclerosis (ALS) , 2010, Behavioural Brain Research.

[13]  G. Miller.  Is pharma running out of brainy ideas? , 2010, Science.

[14]  Albert C. Ludolph,et al.  Guidelines for preclinical animal research in ALS/MND: A consensus meeting , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[15]  H. Geerts.  Of Mice and Men , 2009, CNS drugs.

[16]  L. Jaworska-Feil,et al.  Effects of TRH and its analogues on primary cortical neuronal cell damage induced by various excitotoxic, necrotic and apoptotic agents , 2009, Neuropeptides.

[17]  W. Pardridge.  Alzheimer's disease drug development and the problem of the blood-brain barrier , 2009, Alzheimer's & Dementia.

[18]  Z. Chi,et al.  Alterations of NR2B and PSD-95 expression in hippocampus of kainic acid-exposed rats with behavioural deficits , 2009, Behavioural Brain Research.

[19]  S. Perrin,et al.  No Benefit from Chronic Lithium Dosing in a Sibling-Matched, Gender Balanced, Investigator-Blinded Trial Using a Standard Mouse Model of Familial ALS , 2009, PloS one.

[20]  M. Williams,et al.  Challenges in the Search for Drugs to Treat Central Nervous System Disorders , 2009, Journal of Pharmacology and Experimental Therapeutics.

[21]  David J Brayden,et al.  Conjugation of salmon calcitonin to a combed-shaped end functionalized poly(poly(ethylene glycol) methyl ether methacrylate) yields a bioactive stable conjugate. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[22]  L. Mucke,et al.  Epilepsy and cognitive impairments in Alzheimer disease. , 2009, Archives of neurology.

[23]  S. Przedborski,et al.  Oxidative Stress in Parkinson's Disease , 2008, Annals of the New York Academy of Sciences.

[24]  B. Kalmar,et al.  Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1G93A mouse model of ALS , 2008, Journal of neurochemistry.

[25]  C. Ballini,et al.  Validation of a robust and sensitive method for detecting hydroxyl radical formation together with evoked neurotransmitter release in brain microdialysis , 2008, Journal of neurochemistry.

[26]  P. M. Hinkle,et al.  Corrigendum to “A novel TRH analog, Glp–Asn–Pro–d-Tyr–d-TrpNH2, binds to [3H][3-Me-His2]TRH-labelled sites in rat hippocampus and cortex but not pituitary or heterologous cells expressing TRHR1 or TRHR2” [Neurosci. Lett. 431 (2007) 26–30] , 2008, Neuroscience Letters.

[27]  P. M. Hinkle,et al.  A novel TRH analog, Glp–Asn–Pro–d-Tyr–d-TrpNH2, binds to [3H][3-Me-His2]TRH-labelled sites in rat hippocampus and cortex but not pituitary or heterologous cells expressing TRHR1 or TRHR2 , 2008, Neuroscience Letters.

[28]  Maurizio Recanatini,et al.  Multi-target-directed ligands to combat neurodegenerative diseases. , 2008, Journal of medicinal chemistry.

[29]  J. E. Kranz,et al.  Design, power, and interpretation of studies in the standard murine model of ALS , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[30]  David E. Gloriam,et al.  The G protein-coupled receptor subset of the rat genome , 2007, BMC Genomics.

[31]  M. Pangalos,et al.  Drug development for CNS disorders: strategies for balancing risk and reducing attrition , 2007, Nature Reviews Drug Discovery.

[32]  K. Tipton,et al.  Discovery of a dual action first-in-class peptide that mimics and enhances CNS-mediated actions of thyrotropin-releasing hormone , 2007, Neuropharmacology.

[33]  Xianzeng Liu,et al.  Impaired single cell firing and long‐term potentiation parallels memory impairment following recurrent seizures , 2007, The European journal of neuroscience.

[34]  V. Meininger,et al.  Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: Report on the 142nd ENMC international workshop , 2007, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[35]  L. Mucke,et al.  A network dysfunction perspective on neurodegenerative diseases , 2006, Nature.

[36]  C. Vorhees,et al.  Morris water maze: procedures for assessing spatial and related forms of learning and memory , 2006, Nature Protocols.

[37]  A. Faden,et al.  Neuroprotective effects of novel small peptides in vitro and after brain injury , 2005, Neuropharmacology.

[38]  K. Tipton,et al.  Structure-activity studies with high-affinity inhibitors of pyroglutamyl-peptidase II. , 2005, The Biochemical journal.

[39]  S. O’Mara,et al.  Combining exercise and cyclooxygenase-2 inhibition does not ameliorate learning deficits after brain insult, despite an increase in BDNF levels , 2005, Brain Research.

[40]  W. Pardridge.  Molecular biology of the blood-brain barrier , 2005, Methods in molecular medicine.

[41]  H. Vaudry,et al.  Distribution of the mRNAs encoding the thyrotropin‐releasing hormone (TRH) precursor and three TRH receptors in the brain and pituitary of Xenopus laevis: Effect of background color adaptation on TRH and TRH receptor gene expression , 2004, The Journal of comparative neurology.

[42]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[43]  A. Prange,et al.  The Thyrotropin-Releasing Hormone (TRH) Hypothesis of Homeostatic Regulation: Implications for TRH-Based Therapeutics , 2003, Journal of Pharmacology and Experimental Therapeutics.

[44]  M. Gershengorn,et al.  Pharmacological studies of thyrotropin-releasing hormone (TRH) receptors from Xenopus laevis: is xTRHR3 a TRH receptor? , 2003, Endocrinology.

[45]  M. Gershengorn,et al.  Thyrotropin-releasing hormone receptors -- similarities and differences. , 2003, Journal of molecular endocrinology.

[46]  Susan R. George,et al.  G-Protein-coupled receptor oligomerization and its potential for drug discovery , 2002, Nature Reviews Drug Discovery.

[47]  P. Lory,et al.  Characterization and functional expression of cDNAs encoding thyrotropin-releasing hormone receptor from Xenopus laevis. , 2002, European journal of biochemistry.

[48]  J. A. Kelly,et al.  Pharmacologically distinct binding sites in rat brain for [3H]thyrotropin-releasing hormone (TRH) and [3H][3-methyl-histidine(2)]TRH. , 2002, Biochemical pharmacology.

[49]  E J Park,et al.  Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs. , 2001, The journal of peptide research : official journal of the American Peptide Society.

[50]  R. D'Hooge,et al.  Applications of the Morris water maze in the study of learning and memory , 2001, Brain Research Reviews.

[51]  D. Middlemiss,et al.  Characterization of [125I]‐SB‐258585 binding to human recombinant and native 5‐HT6 receptors in rat, pig and human brain tissue , 2000 .

[52]  K. Tipton,et al.  Kinetic Investigation of the Specificity of Porcine Brain Thyrotropin-releasing Hormone-degrading Ectoenzyme for Thyrotropin-releasing Hormone-like Peptides* , 2000, The Journal of Biological Chemistry.

[53]  Ole A. Andreassen,et al.  Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis , 1999, Nature Medicine.

[54]  K Payza,et al.  Cloning and Characterization of a cDNA Encoding a Novel Subtype of Rat Thyrotropin-releasing Hormone Receptor* , 1998, The Journal of Biological Chemistry.

[55]  H. Iwaasa,et al.  Cloning and characterization of a new subtype of thyrotropin-releasing hormone receptors. , 1998, Biochemical and biophysical research communications.

[56]  K. Hashimoto,et al.  A novel transcript for the thyrotropin-releasing hormone receptor in human pituitary and pituitary tumors. , 1997, The Journal of clinical endocrinology and metabolism.

[57]  M. Gurney,et al.  Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. , 1994, Science.

[58]  G. Holmes,et al.  Neuroprotective Effect of Felbamate After Kainic Acid‐Induced Status Epilepticus , 1993, Epilepsia.

[59]  W. Pardridge,et al.  Capillary Depletion Method for Quantification of Blood–Brain Barrier Transport of Circulating Peptides and Plasma Proteins , 1990, Journal of neurochemistry.

[60]  E. Griffiths.  Clinical applications of thyrotrophin-releasing hormone. , 1987, Clinical science.

[61]  T. Rainbow,et al.  Autoradiographic localization of thyr tropin releasing hormone receptors in human brain , 1986, Neurology.

[62]  C. Parker,et al.  Thyrotropin releasing hormone (TRH) binding sites in the adult human brain: Localization and characterization , 1984, Peptides.

[63]  G. Boschi,et al.  Antinociceptive properties of thyrotropin releasing hormone in mice: comparison with morphine , 1983, British journal of pharmacology.

[64]  J. Hershman.  Clinical Application of Thyrotropin-Releasing Hormone , 1974 .

[65]  A. McKee,et al.  The spectrum of disease in chronic traumatic encephalopathy. , 2013, Brain : a journal of neurology.

[66]  Stuart Maudsley,et al.  The role of Thyrotropin Releasing Hormone in aging and neurodegenerative diseases. , 2013, American journal of Alzheimer's disease.

[67]  B. Stoica,et al.  Multifunctional drug treatment in neurotrauma , 2011, Neurotherapeutics.

[68]  M. Khrestchatisky,et al.  Synthetic therapeutic peptides: science and market. , 2010, Drug discovery today.

[69]  Thomas Steckler,et al.  Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models , 2009, Neuropsychopharmacology.

[70]  A. Prange,et al.  The thyrotropin-releasing hormone (TRH)-immune system homeostatic hypothesis. , 2009, Pharmacology & therapeutics.

[71]  Mario Delgado,et al.  Regulation of immune tolerance by anti-inflammatory neuropeptides , 2007, Nature Reviews Immunology.

[72]  M. Kubek,et al.  Thyrotropin-releasing hormone in the treatment of intractable epilepsy. , 2002, Pediatric neurology.

[73]  B. O'dowd,et al.  TRH-R2 exhibits similar binding and acute signaling but distinct regulation and anatomic distribution compared with TRH-R1. , 2000, Molecular endocrinology.

[74]  J. A. Kelly.  Thyrotropin-releasing hormone: basis and potential for its therapeutic use. , 1995, Essays in biochemistry.